Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The significant decline in revenue and increased net loss indicate financial struggles, despite cost-cutting measures. The competitive landscape for FG-3246 and strategic execution risks further exacerbate concerns. The Q&A session revealed management's uncertainties about strategic partnerships and trial metrics, adding to the negative sentiment. These factors suggest a likely negative stock price movement.
Key Financial Performance
Total Revenue (Q4 2025) $1.3 million, a decrease from $3.1 million in Q4 2024. The decline was not explicitly explained in the transcript.
Total Revenue (Full Year 2025) $6.4 million, a decrease from $29.6 million in 2024. The decline was not explicitly explained in the transcript.
Total Operating Costs and Expenses (Q4 2025) $14.8 million, an increase from $10.3 million in Q4 2024. The increase was not explicitly explained in the transcript.
Total Operating Costs and Expenses (Full Year 2025) $52.3 million, a decrease from $180 million in 2024. The reduction reflects cost-cutting measures to reduce fixed cost infrastructure.
R&D Expenses (Q4 2025) $7.3 million, an increase from $6.9 million in Q4 2024. The increase was not explicitly explained in the transcript.
R&D Expenses (Full Year 2025) $23.5 million, a decrease from $95.7 million in 2024. The reduction reflects cost-cutting measures to reduce fixed cost infrastructure.
SG&A Expenses (Q4 2025) $7.3 million, a decrease from $8.3 million in Q4 2024. The decrease was not explicitly explained in the transcript.
SG&A Expenses (Full Year 2025) $27.7 million, a decrease from $49.3 million in 2024. The reduction reflects cost-cutting measures to reduce fixed cost infrastructure.
Net Loss (Q4 2025) $14.6 million or $3.61 per share, an increase from $8.7 million or $2.15 per share in Q4 2024. The increase was not explicitly explained in the transcript.
Net Loss (Full Year 2025) $58.2 million or $14.40 per share, a decrease from $153.1 million or $38.26 per share in 2024. The reduction reflects cost-cutting measures to reduce fixed cost infrastructure.
Cash, Cash Equivalents, Investments, and Accounts Receivable (End of 2025) $109.4 million, ensuring a cash runway into 2028.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FG-3246 and FG-3180: Initiated Phase II trial for FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer (mCRPC). Interim results expected in the second half of 2026. FG-3246 targets CD46, a novel tumor-selective epitope, with a potential market of over $5 billion annually in the U.S. FG-3180 serves as a companion PET imaging agent.
Roxadustat: Submitted Phase III protocol for anemia due to lower-risk myelodysplastic syndromes (MDS). Received Orphan Drug Designation for MDS. Phase III trial initiation targeted for the second half of 2026.
Prostate Cancer Market: FG-3246 addresses a significant unmet need in late-stage prostate cancer, with a potential U.S. market of over $5 billion annually.
Anemia in MDS: Roxadustat targets approximately 49,000 patients in the U.S. with anemia associated with lower-risk MDS, offering a significant market opportunity with no current oral treatments available.
Financial Restructuring: Completed the sale of FibroGen China to AstraZeneca, paid off senior secured term loan, and extended cash runway into 2028.
Rebranding: Rebranded from FibroGen to Kyntra Bio to reflect focus on oncology and rare diseases.
Pipeline Focus: Focused on advancing FG-3246 and FG-3180 for mCRPC and roxadustat for anemia in MDS, with multiple clinical milestones planned into 2028.
Partnerships: Exploring strategic partnerships for the development of roxadustat.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Feedback and Trial Design: The company is awaiting feedback from the FDA on the Phase III trial design for roxadustat, which could delay the initiation of the trial if feedback requires significant adjustments.
Clinical Trial Enrollment and Results: The ongoing Phase II monotherapy trial for FG-3246 and FG-3180 is actively enrolling patients, but delays in enrollment or failure to meet interim results expectations could impact timelines and strategic objectives.
Safety Concerns in Trials: The incidence of grade 3 or greater neutropenia in earlier trials, although mitigated with G-CSF prophylaxis, remains a potential safety concern that could affect patient outcomes and trial success.
Financial Performance: The company reported a significant decline in revenue from $29.6 million in 2024 to $6.4 million in 2025, which could impact its ability to fund future operations and trials despite an extended cash runway into 2028.
Market Competition: FG-3246 faces competition from other prostate cancer treatments, particularly those targeting PSMA, which could limit its market share despite its novel CD46 targeting approach.
Strategic Execution Risks: The company’s ability to achieve a median rPFS of 10 months or greater in the Phase II trial is critical for commercial competitiveness, and failure to do so could undermine its strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FG-3246 and FG-3180 Program: The company is actively enrolling patients in the Phase II monotherapy dose optimization trial for FG-3246 in metastatic castration-resistant prostate cancer (mCRPC). Interim results, including PSA50, ORR, safety, PK, and exposure response data, are expected in the second half of 2026. Mature rPFS data is anticipated in 2027. The trial aims to improve upon the 8.7 months of median rPFS observed in the Phase I trial, targeting a benchmark of 10 months or greater for commercial competitiveness.
Roxadustat for Anemia in Lower-Risk MDS: The company plans to initiate a Phase III trial for roxadustat in the second half of 2026, targeting patients with anemia associated with lower-risk myelodysplastic syndromes (MDS). The trial will focus on patients refractory to or ineligible for prior ESA treatment, with the potential to demonstrate efficacy across RS-positive and RS-negative patients. Feedback on the trial design from the FDA is expected in the coming weeks.
Financial Guidance: The company has extended its cash runway into 2028, supported by a simplified capital structure and reduced fixed costs. This financial position enables investment in U.S. pipeline opportunities and supports multiple clinical milestones.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the potential commercial opportunity for CD46 imaging agents compared to PSMA imaging agents?
A:The management anticipates that if FG-3246 makes it to market, it would follow a similar playbook to Pluvicto, requiring patients to undergo a CD46 PET imaging agent scan and show positivity. They acknowledge that companies like Telix and Lantheus have more expertise in this space and are evaluating the role Kyntra Bio should play versus potential strategic partners. The differentiation of their ADC in CD46-positive patients could justify its use in the treatment algorithm.
Q:What is the significance of SUV data in patient selection for CD46 imaging agents?
A:The Phase II trial is designed to define CD46 positivity, which might be based on SUV or other metrics. Management stated it is too early to comment definitively as they are still evaluating metrics outside of SUV as part of the Phase II trial.
Q:What is the expected balance of patients between the IST and the monotherapy study for the 3246 program?
A:In the IST, about 60% of patients had progressed on 2 or more ARPIs, while 40% had progressed on only 1 ARPI. In the Phase II monotherapy trial, 100% of patients will have progressed on only 1 prior ARPI and be in the pre-chemo setting. This differentiation aligns with the efficacy benchmarks established by PSMA-4.
Q:Are there any updates on the roxadustat program and potential partnering efforts?
A:Management stated they are evaluating the opportunity to develop roxadustat internally versus collaborating with a strategic partner. However, they are not ready to comment further on the specifics of these efforts.
Q:Why is there a delay in the FDA's feedback on the IND for roxadustat despite its orphan status?
A:The FDA was informed that the Phase III trial would not start imminently when the protocol was submitted. As a result, the FDA signaled a feedback timeline of 60 to 90 days instead of the typical 30 days. Management expects feedback in the coming weeks based on this guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the maturity level of potential partnering or business development efforts for the roxadustat program, using vague language and stating they are not ready to comment further.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC
CD
FG
III trial
IST
Kyntra Bio
PET
PSA
Phase III
Phase monotherapy
Slide
anemia risk
approach
cash
castration
combination
design
development
expression
line
loss
monotherapy trial
month
opportunity
patient
potential
prostate cancer
rPFS
response
result
risk MDS
roxadustat
stage
statement
study
today
treatment
tumor
KYNB Transcript
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Positive5-11
The earnings call presents a positive outlook, with a 15% revenue increase and strong sales in oncology. Operating margin improvement and cash flow growth further support this sentiment. Collaborations with AstraZeneca and Astellas add strategic value, despite associated risks. The absence of negative analyst sentiment in the Q&A and a cash runway extended to 2028 enhance the positive outlook. Overall, these factors suggest a likely stock price increase of 2% to 8% in the short term.
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
Unknown3-16
The significant decline in revenue and increased net loss indicate financial struggles, despite cost-cutting measures. The competitive landscape for FG-3246 and strategic execution risks further exacerbate concerns. The Q&A session revealed management's uncertainties about strategic partnerships and trial metrics, adding to the negative sentiment. These factors suggest a likely negative stock price movement.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
